HC Wainwright Comments on Personalis, Inc.’s FY2024 Earnings (NASDAQ:PSNL)

Personalis, Inc. (NASDAQ:PSNL) – Investment analysts at HC Wainwright cut their FY2024 earnings estimates for shares of Personalis in a research report issued on Monday, August 19th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($1.01) for the year, down from their previous forecast of ($0.95). HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Personalis’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Personalis’ Q4 2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.21) EPS and FY2025 earnings at ($0.89) EPS.

A number of other research analysts have also recently commented on PSNL. Needham & Company LLC raised their price target on shares of Personalis from $5.50 to $7.25 and gave the stock a “buy” rating in a research note on Friday, August 16th. BTIG Research raised their price target on shares of Personalis from $5.50 to $7.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Finally, Lake Street Capital initiated coverage on shares of Personalis in a research note on Tuesday, April 30th. They set a “buy” rating and a $4.00 price target for the company.

Personalis Stock Performance

NASDAQ PSNL opened at $5.71 on Wednesday. The firm has a 50-day simple moving average of $2.63 and a 200 day simple moving average of $1.84. Personalis has a twelve month low of $0.89 and a twelve month high of $7.20. The stock has a market cap of $303.09 million, a PE ratio of -3.01 and a beta of 1.85.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.10. Personalis had a negative net margin of 101.78% and a negative return on equity of 56.87%. The business had revenue of $22.58 million during the quarter, compared to analyst estimates of $19.81 million. During the same quarter in the prior year, the business earned ($0.50) earnings per share.

Institutional Trading of Personalis

Several institutional investors and hedge funds have recently made changes to their positions in PSNL. Public Employees Retirement System of Ohio bought a new position in shares of Personalis in the 1st quarter valued at about $29,000. Virtu Financial LLC bought a new stake in shares of Personalis during the first quarter worth $41,000. Price T Rowe Associates Inc. MD grew its stake in shares of Personalis by 58.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 95,000 shares of the company’s stock worth $142,000 after buying an additional 34,900 shares during the last quarter. Quadrature Capital Ltd bought a new stake in shares of Personalis during the fourth quarter worth $152,000. Finally, Howland Capital Management LLC grew its stake in shares of Personalis by 392.8% in the first quarter. Howland Capital Management LLC now owns 211,118 shares of the company’s stock worth $315,000 after purchasing an additional 168,274 shares during the last quarter. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.